INTERCEPT PHARMACEUTICALS IN (ICPT)
US45845P1084 - Common Stock
We assign a fundamental rating of 2 out of 10 to ICPT. ICPT was compared to 588 industry peers in the Biotechnology industry. ICPT may be in some trouble as it scores bad on both profitability and health. ICPT has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
ICPT had negative earnings in the past year.
ICPT had a negative operating cash flow in the past year.
ICPT had negative earnings in 4 of the past 5 years.
ICPT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ICPT has a Return On Assets of -15.67%. This is amongst the best in the industry. ICPT outperforms 84.91% of its industry peers.
Looking at the Return On Equity, with a value of -85.76%, ICPT is in line with its industry, outperforming 45.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.67% | ||
| ROE | -85.76% | ||
| ROIC | N/A |
ROA(3y)-8.21%
ROA(5y)-26.21%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 99.80%, ICPT belongs to the top of the industry, outperforming 99.17% of the companies in the same industry.
ICPT's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ICPT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.8% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.45%
GM growth 5Y0.15%
2. Health
2.1 Basic Checks
ICPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
ICPT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ICPT has more shares outstanding
The debt/assets ratio for ICPT has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -5.03, we must say that ICPT is in the distress zone and has some risk of bankruptcy.
ICPT has a Altman-Z score of -5.03. This is in the lower half of the industry: ICPT underperforms 66.17% of its industry peers.
ICPT has a Debt/Equity ratio of 3.12. This is a high value indicating a heavy dependency on external financing.
ICPT has a Debt to Equity ratio of 3.12. This is amonst the worse of the industry: ICPT underperforms 85.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.12 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.03 |
ROIC/WACCN/A
WACC10.19%
2.3 Liquidity
A Current Ratio of 4.22 indicates that ICPT has no problem at all paying its short term obligations.
The Current ratio of ICPT (4.22) is comparable to the rest of the industry.
A Quick Ratio of 4.22 indicates that ICPT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.22, ICPT is in line with its industry, outperforming 43.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.22 | ||
| Quick Ratio | 4.22 |
3. Growth
3.1 Past
ICPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -125.05%.
The Revenue has grown by 14.64% in the past year. This is quite good.
Measured over the past years, ICPT shows a quite strong growth in Revenue. The Revenue has been growing by 16.88% on average per year.
EPS 1Y (TTM)-125.05%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-98.97%
Revenue 1Y (TTM)14.64%
Revenue growth 3Y4.27%
Revenue growth 5Y16.88%
Revenue growth Q2Q14.44%
3.2 Future
Based on estimates for the next years, ICPT will show a very negative growth in Earnings Per Share. The EPS will decrease by -22.89% on average per year.
Based on estimates for the next years, ICPT will show a small growth in Revenue. The Revenue will grow by 1.71% on average per year.
EPS Next Y-122.07%
EPS Next 2Y-41.22%
EPS Next 3Y-33.62%
EPS Next 5Y-22.89%
Revenue Next Year3.67%
Revenue Next 2Y6.35%
Revenue Next 3Y4.21%
Revenue Next 5Y1.71%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ICPT. In the last year negative earnings were reported.
ICPT is valuated reasonably with a Price/Forward Earnings ratio of 9.11.
99.00% of the companies in the same industry are more expensive than ICPT, based on the Price/Forward Earnings ratio.
ICPT's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 9.11 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as ICPT's earnings are expected to decrease with -33.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.22%
EPS Next 3Y-33.62%
5. Dividend
5.1 Amount
ICPT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INTERCEPT PHARMACEUTICALS IN
NASDAQ:ICPT (11/7/2023, 7:02:20 PM)
After market: 19 0 (0%)19
+0.04 (+0.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap794.39M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 9.11 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.67% | ||
| ROE | -85.76% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.8% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.12 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.22 | ||
| Quick Ratio | 4.22 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-125.05%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-122.07%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)14.64%
Revenue growth 3Y4.27%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y